Antiphospholipid syndrome (APS) is associated with an increased risk of thrombosis which is medicated by impairment of fibrinolysis, reduction in protein C activity, procoagulant effects on platelets and endothelial cells, and induction of vascular endothelial growth factor (VEGF).2, 3, 10. This evidence concerns the gene VEGFA and deep vein thrombosis.